Skip to main content
Search

# Astromech acquisition of Form Bio

1 related articles

Subscribe to updates
  1. Biotechnology

    Astromech buys Form Bio for $230 million in stock, putting evolutionary models and genetic-medicine design under one roof

    Astromech announced an all-stock acquisition of Form Bio valued at $230 million, placing cross-species evolutionary modeling and genetic-medicine design tools inside one company. The two capabilities previously sat in separate organizations: one inferred biological function from conserved sequence, the other turned sequence into genetic constructs researchers can build and test. The combined aim is to cut unwanted components at the design stage and potentially reduce downstream purification; Form Bio's Duchenne muscular dystrophy work raised full-genome content from 13% to 59% in under 30 days through promoter sequence-level redesign.

You’re all caught up